| Literature DB >> 28905878 |
Grégoire Davy1,2, Antoine Rousselin1,2, Nicolas Goardon1,2, Laurent Castéra1,2, Valentin Harter3, Angelina Legros1, Etienne Muller1,2, Robin Fouillet1, Baptiste Brault1,2, Anna S Smirnova2, Fréderic Lemoine4, Pierre de la Grange4, Marine Guillaud-Bataille5, Virginie Caux-Moncoutier6,7, Claude Houdayer6,7,8, Françoise Bonnet9, Cécile Blanc-Fournier10,11, Pascaline Gaildrat2, Thierry Frebourg2,12, Alexandra Martins2, Dominique Vaur1,2, Sophie Krieger1,2,13.
Abstract
Interpretation of variants of unknown significance (VUS) is a major challenge for laboratories performing molecular diagnosis of hereditary breast and ovarian cancer (HBOC), especially considering that many genes are now known to be involved in this syndrome. One important way these VUS can have a functional impact is through their effects on RNA splicing. Here we present a custom RNA-Seq assay plus bioinformatics and biostatistics pipeline to analyse specifically alternative and abnormal splicing junctions in 11 targeted HBOC genes. Our pipeline identified 14 new alternative splices in BRCA1 and BRCA2 in addition to detecting the majority of known alternative spliced transcripts therein. We provide here the first global splicing pattern analysis for the other nine genes, which will enable a comprehensive interpretation of splicing defects caused by VUS in HBOC. Previously known splicing alterations were consistently detected, occasionally with a more complex splicing pattern than expected. We also found that splicing in the 11 genes is similar in blood and breast tissue, supporting the utility and simplicity of blood splicing assays. Our pipeline is ready to be integrated into standard molecular diagnosis for HBOC, but it could equally be adapted for an integrative analysis of any multigene disorder.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28905878 PMCID: PMC5602017 DOI: 10.1038/ejhg.2017.116
Source DB: PubMed Journal: Eur J Hum Genet ISSN: 1018-4813 Impact factor: 4.246